Herein, we have followed a comparative protein expression profiling of tumor and NAT in a cohort of LUAD by RPPA using specific antibodies to portray a relevant fraction of the metabolic reprogramming experienced by this type of carcinomas. This evidence concerns the gene BRD2 and neoplasm.